deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03498612

Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

Sponsor: Merck Sharp & Dohme LLC

Conditions Follicular Lymphoma Indolent B-Cell Non-Hodgkin Lymphoma Marginal Zone Lymphoma
Interventions Laboratory Biomarker Analysis Pembrolizumab
Updated 24 times since 2018 Last updated: Oct 28, 2025 Started: Jul 9, 2018 Primary completion: Jun 9, 2021 Completion: Aug 29, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Closed per SRC Low Accrual Policy.

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

Other Follicular Lymphoma trials with similar outcome

Browse all Follicular Lymphoma trials

This PHASE2 trial investigates Follicular Lymphoma and Indolent B-Cell Non-Hodgkin Lymphoma and is currently terminated or withdrawn. Merck Sharp & Dohme LLC leads this study, which shows 24 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Dec 2018 · 4 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Jun 2019 · 5 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Feb 2020 · 5 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Feb 2023 · 8 months · monthly snapshot~Feb 2023 – ~Sep 2023 · 7 months · monthly snapshot~Sep 2023 – ~Apr 2024 · 7 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Feb 2025 · 4 months · monthly snapshot~Feb 2025 – ~Dec 2025 · 10 months · monthly snapshot~Dec 2025 – present · 9 months · monthly snapshot

Change History

24 versions recorded

  1. Dec 2025 — Present [monthly]

    Terminated PHASE2

  2. Feb 2025 — Dec 2025 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  3. Oct 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 19 earlier versions

  1. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Feb 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jun 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  5. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  6. Feb 2022 — May 2022 [monthly]

    Recruiting PHASE2

  7. Sep 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  8. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  9. May 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  10. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE2

  11. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  12. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  13. Sep 2019 — Feb 2020 [monthly]

    Recruiting PHASE2

  14. Jun 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  15. Jan 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  16. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  17. Aug 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  18. Jun 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE2

  19. May 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • University of Washington
Data source: University of Washington

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations